Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development (Q34335631)

1 August 2017

1 reference

title

Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development (English)

1 reference

1 August 2017

1 reference

Lieberman R

1

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 August 2001

1 reference

1 August 2017

1 reference

1 August 2017

volume

58

1 reference

1 August 2017

issue

2 Suppl 1

1 reference

1 August 2017

page(s)

83-90

1 reference

Prostate cancer chemoprevention: Strategies for designing efficient clinical trials

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Hormone refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

STUDIES ON PROSTATIC CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Decrease of prostatic intraepithelial neoplasia following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Prostatic intraepithelial neoplasia and endocrine manipulation

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Design of the Prostate Cancer Prevention Trial (PCPT).

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Mechanism of androgen receptor activation and possible implications for chemoprevention trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Use of animal models in defining efficacy of chemoprevention agents against prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

High-grade prostatic intraepithelial neoplasia in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Prostate Cancer and Supplementation With α-Tocopherol and β-Carotene: Incidence and Mortality in a Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Activation of the androgen receptor by polypeptide growth factors and cellular regulators

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Expression profiling using cDNA microarrays

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

New molecular approaches for identifying novel targets, mechanisms, and biomarkers for prostate cancer chemopreventive agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Low-dose difluoromethylornithine and polyamine levels in human prostate tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Alpha-difluoromethylornithine and polyamine levels in the human prostate: results of a phase IIa trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Diet and its preventive role in prostatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Anti-androgens and other hormonal therapies for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Tamoxifen for flutamide/finasteride-induced gynecomastia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Non-steroidal anti-inflammatory drugs and prostate cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2801%2901247-X

7 January 2021

10.1016/S0090-4295(01)01247-X

Identifiers

DOI

1 reference

1 August 2017

1 reference